PROBIOTICOTERAPIA NO MANEJO NUTRICIONAL DA SÍNDROME DO INTESTINO IRRITÁVEL: UM ESTUDO DE REVISÃO
Palavras-chave
Downloads
Resumo
A síndrome do intestino irritável (SII) é um distúrbio funcional gastrointestinal que pode causar dor e distensão abdominal, flatulências, irritabilidade, ansiedade e depressão. Sua classificação pode variar de acordo com a predominância ao hábito intestinal de constipação, diarreia ou mista. Seu diagnóstico é baseado em sintomatologias e na ausência de outras doenças relacionadas ao trato gastrointestinal. O tratamento pode variar entre farmacológico, dietoterapia, e uso de suplementos, onde vem se destacando o interesse pelo uso de probióticos. O estudo objetivou verificar as repercussões do uso de probióticos no manejo nutricional de portadores da SII. Trata-se de uma revisão bibliográfica narrativa da literatura, utilizando artigos científicos das bases de dados PubMed, SciELO e Science Direct, nos idiomas inglês e português, no qual foram selecionados um total de 30 estudos, sendo os 7 principais destacados em tabela. A suplementação de probiótico, associada a uma dieta equilibrada, com a redução de alimentos fermentativos, corroboram tanto com a redução e controle dos sintomas, como também na qualidade de vida dos portadores de SII.
Biografia do Autor
Universidade Maurício de Nassau
Doutoranda e Mestre pela Universidade Federal de Pernambuco.
Universidade Maurício de Nassau
Universidade Maurício de Nassau
Universidade Maurício de Nassau
Universidade Maurício de Nassau
Referências
Liu J, Chey WD, Haller E, Eswaran S. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Know and What We Have Yet to Learn. Annu Rev Med. 2020;71:303–14 DOI: https://doi.org/10.1146/annurev-med-050218-013625
Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289–310 DOI: https://doi.org/10.1007/s12325-018-0673-5
Cozma-Petrut A, Loghin F, Miere D, Dumitrascu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! World J Gastroenterol. 2017;23(21):3771–83 DOI: https://doi.org/10.3748/wjg.v23.i21.3771
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(8):473–86. Available from: http://dx.doi.org/10.1038/s41575-020-0286-8
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Prim. 2016;2(March):1–24 DOI: https://doi.org/10.1038/nrdp.2016.14
Santos T. Síndrome do Intestino Irritável e Dieta com restrição de FODMAPs. Lisboa: Universidade de Lisboa; 2016. URI: http://hdl.handle.net/10451/29541
Altobelli E, Del Negro V, Angeletti P, Latella G. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients [Internet]. 2017 Aug 26;9(9):940. Available from: http://www.mdpi.com/2072-6643/9/9/940
Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes [Internet]. 2016;7(5):365–83. Available from: http://dx.doi.org/10.1080/19490976.2016.1218585
Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP. New insights into irritable bowel syndrome: From pathophysiology to treatment. Ann Gastroenterol. 2019;32(6):554–64 DOI: https://doi.org/10.20524/aog.2019.0428
Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):28–35 DOI: https://doi.org/10.1097/MED.0000000000000523
Ticinesi A, Nouvenne A, Tana C, Prati B, Cerundolo N, Miraglia C, et al. The impact of intestinal microbiota on bio-medical research: Definitions, techniques and physiology of a “new frontier.” Acta Biomed. 2018;89:52–9 DOI: https://doi.org/10.23750/abm.v89i9-S.7906
Martoni CJ, Srivastava S, Leyer GJ. lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome : Randomized Controlled Trial. Nutrients. 2020;12(363):1–15 DOI: https://doi.org/10.3390/nu12020363
Valdovinos-García LR, Abreu AT, Valdovinos-Díaz MA. Probiotic use in clinical practice: Results of a national survey of gastroenterologists and nutritionists. Rev Gastroenterol Mex [Internet]. 2019;84(3):303–9. Available from: https://doi.org/10.1016/j.rgmx.2018.05.004
Brun P, Scarpa M, Marchiori C, Sarasin G, Caputi V, Porzionato A, et al. Correction: Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS (PLoS ONE (2017) 12:7 (e0181863) PLoS One. 2017;12(11) DOI: https://doi.org/10.1371/journal.pone.0181863)
Chen Q, Ren Y, Lu J, Bartlett M, Chen L, Zhang Y, et al. A novel prebiotic blend product prevents irritable bowel syndrome in mice by improving gut microbiota and modulating immune response. Nutrients. 2017;9(12) DOI: https://doi.org/10.3390/nu9121341
Hong KB, Seo H, Lee JS, Park Y. Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model. BMC Complement Altern Med. 2019;19(1):1–8 DOI: https://doi.org/10.1186/s12906-019-2610-9
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044–60 DOI: https://doi.org/10.1111/apto.15001
Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: An ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):1–8 DOI: https://doi.org/10.1186/s12876-017-0605-x
Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients [Internet]. 2019 Sep 2;11(9):2048. Available from: https://www.mdpi.com/2072-6643/11/9/2048 DOI: https://doi.org/10.3390/nu11092048
Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients [Internet]. 2017 Sep 15;9(9):1021. Available from: https://www.mdpi.com/2072-6643/9/9/1021 doi.org/10.3390/nu9091021
Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of Action of Probiotics. Adv Nutr. 2019;10:S49–66 DOI: https://doi.org/10.1093/avanços/nmy063
Gouba N, Hien YE, Guissou ML, Fonkou MDM, Traoré Y, Tarnagda Z. Digestive tract mycobiota and microbiota and the effects on the immune system. Hum Microbiome J [Internet]. 2019;12(May):100056. Available from: https://doi.org/10.1016/j.humic.2019.100056
Sekirov I, Russell SL, Caetano M Antunes L, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904 DOI: https://doi.org/10.1152/physrev.00045.2009
Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro. 2015;7(1):1–20 DOI: https://doi.org/10.1177/1759091414568185
Passos M do CF, Moraes-Filho JP. Microbiota intestinal nas doenças digestivas. Arq Gastroenterol. 2017;54(3):255–62 DOI: https://doi.org/10.1590/S0004-2803.201700000-31
Fasano A. All disease begins in the ( leaky ) gut : role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases [ version 1 ; peer review : 3 approved ] Alessio Fasano. F1000Research. 2020;9:1–12 DOI: https://doi.org/10.12688/f1000research.20510.1
Liu Y, Tran DQ, Rhoads JM. Probiotics in Disease Prevention and Treatment. J Clin Pharmacol [Internet]. 2018 Oct;58:S164–79. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jcph.1121
Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am [Internet]. 2019;103(1):137–52. Available from: https://doi.org/10.1016/j.mcna.2018.08.006
Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, et al. Health Gut Microbiota. Nutrients. 2019;1–23 DOI: https://doi.org/10.3390/nu11102393
Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med [Internet]. 2017;129(8):872–88. Available from: https://doi.org/10.1080/00325481.2017.1383819
Licença
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.